Techedge to acquire Chinese vaccine producer

Published: 11-Apr-2006

The New Jersey-based group Techedge plans to acquire China BioPharma (CBP), a Cayman Island company with majority ownership rights to Tianyuan Bio-pharmaceuticals Co in Zhejiang Province, China.


The New Jersey-based group Techedge plans to acquire China BioPharma (CBP), a Cayman Island company with majority ownership rights to Tianyuan Bio-pharmaceuticals Co in Zhejiang Province, China.

Techedge, a developer of mobile VoIP and wireless broadband solutions, recently repositioned itself to focus on opportunities in the fast growing bio-pharmaceutical sector in China. It will acquire 100% of the outstanding capital stock of CBP in exchange for 3,000,000 unregistered shares of Techedge's common stock to be issued.

Tianyuan Bio-pharmaceutical Co is one of China's largest non-governmental owned vaccine research manufacturers and is approved to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (Ebola) and influenza. The company plans to start producing several new vaccines.

Peter Wang, ceo of Techedge said: "With this acquisition, together with China BioPharma, we will bring more international expertise, technologies, and management into Tianyuan Bio-Pharmaceutical and help expand the marketing capability beyond China. This acquisition will make Tianyuan Bio-Pharmaceutical a much stronger company".

You may also like